Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.


Options:
A: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4
B: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab
C: Arm Label: Active Treatment (10 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (10 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID
D: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)

Answer: B